Home Tags MMAE

Tag: MMAE

Four Ways to Show Nonobviousness of ADC Inventions

As research continues to progress and the scientific community’s appreciation for the power of ADCs has grown, so have the numbers. FDA has now approved at least four ADCs, and hundreds more are in development. The number of patent applications has also grown, with the U.S. Patent and Trademark Office (USPTO) publishing over two hundred patent applications with claims to ADC inventions in the last two years alone.

ADCs – The Dawn of a New Era?

Two decades ago, ADCs were hailed as a major breakthrough, especially in the area of oncology therapeutics. The concept of delivering a potent drug payload directly to the site of the tumor for maximum effect with minimal damage caused to non-cancerous cells was viewed as, if not the Holy Grail of cancer treatment, at least a significant advance towards precision medicine. However, the concept has proved difficult to translate into clinical success.

New Hydrophilic Auristatin Payload Improves Antibody-Drug Conjugate Efficacy and Biocompatibility

Antibody-drug conjugates or ADCs, which link an antibody to a potent, small-molecule, cytotoxic, cell-killing, chemotherapeutic agent, use the target-specificity of monoclonal antibodies or antibody...

New Phase I Study with SGN-CD48A in Relapsed or Refractory Multiple...

Multiple myeloma is an incurable hematologic malignancy formed by malignant or transformed plasma cells in which the cancerous plasma cells can crowd out healthy...

Updated Phase I Data for Ladiratuzumab Vedotin in Patients with Triple...

Data from an ongoing phase I clinical trial evaluating ladiratuzumab vedotin, also known as SGN-LIV1A, in patients with metastatic triple negative breast cancer presented...

Antibody-Drug Conjugates at the 59th American Society of Hematology Annual...

This year, in Atlanta, the South's largest and most vibrant city, the 59th annual meeting and exposition of the American Society of Hematology, to...

Seattle Genetics and Astellas Pharma Evaluate Enfortumab Vedotin as Monotherapy in...

Seattle Genetics and Astellas Pharma today confirmed dosing the first patient in EV-201, a registrational phase II clinical trial of enfortumab vedotin as a...

Phase II Trial of Tisotumab Vedotin in Advanced Cervical Cancer Provides...

Genmab and Seattle Genetics confirmed their decision to start a Phase II study of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer....

Seattle Genetics to Co-develop Tisotumab Vedodin with Genmab for the Treatment...

Genmab, an international biotechnology company headquartered in Copenhagen, Denmark, and Seattle Genetics, confirmed that Seattle Genetics has exercised its option to co-develop tisotumab vedotin. The...

Brentuximab Vedotin Approved by Health Canada for Post-ASCT Consolidation Treatment of...

Health Canada, the federal department responsible for helping Canadians maintain and improve their health, has issued a non-conditional marketing authorization for use of brentuximab...